Sajad Khiali

Scopus Publications

Omega-3 fatty acid supplementation in solid organ transplant recipients: A systematic review and meta-analysis of randomized controlled trials
Sama Samankan, Afshin Gharekhani, Sajad Khiali, Afraa Rezagholizadeh, Amin Agabalazadeha, et al.
Clinical Nutrition Espen, 2025
Effects of colchicine on depression scale scores of patients with chronic heart failure with reduced ejection fraction: A randomized clinical trial
Mohammadreza Taban-Sadeghi, Sajad Khiali, Mahsa Karimi, Mehrdad Shahidi, Elnaz Khani, et al.
Journal of Cardiovascular and Thoracic Research, 2025
Introduction: Since there is a bidirectional interaction between heart failure (HF) and depression, we aimed to evaluate the effects of colchicine on depression scale scores in individuals with HF with reduced ejection fraction (HFrEF). Methods: A randomized clinical trial was carried out on 50 patients with HFrEF. The intervention group (n=25) received colchicine 0.5 mg twice a day plus standard care for HFrEF, while the control group (n=25) received only standard care. The study’s primary outcome was the changes in the 21-item Hamilton Depression Rating Scale (HDRS-21) over 12 weeks. Results: During the study period, HDRS-21 significantly decreased in both groups (both P<0.05); however, there were no significant differences between the study groups at baseline (12.2±2.9 vs. 10.5±2.9; P=0.54), week 4 (6.6±2 vs. 5.8±4.7; P=0.21), and week 12 (2.1±2 vs. 4.2±4.5; P=0.11). Conclusion: This study shows that colchicine had no significant effect on HDRS-21 in individuals with HFrEF. Further studies are warranted to confirm the study hypothesis.
Efficacy and Safety of SGLT2 Inhibitors in Individuals with Sold Organ Transplantation: A Systematic Review and Metaanalysis
Sajad Khiali, Mohammadreza Ardalan, Ali Sharifi, Amin Sadrazar, Afra Rezagholizadeh, et al.
Pharmaceutical Sciences, 2025
Despite the growing body of evidence supporting the beneficial effects of sodium-glucose transporter 2 (SGLT-2) inhibitors on metabolic, cardiovascular, renal, and mortality outcomes in the wide range of diseases, clinical data in patients with solid organ transplantation (SOT) is limited. A systematic literature search was conducted in PubMed, Scopus, and Web of Science from database inception until April 14, 2025, to evaluate the efficacy and safety of SGLT-2 inhibitors in patients with SOT. Among 25 studies, 18 included kidney transplant recipients. There was considerable heterogeneity between the remaining studies regarding design, setting, and outcomes. The meta-analysis of two interventional studies showed the beneficial effects of SGLT-2 inhibitors on body mass index (BMI) (-2.564, 95% CI: -4.982 to -0.146, I²=0%, P=0.0377), weight (-0.800, 95% CI: -0.878 to -0.722, I²=0%, P<0.0001), and hemoglobin A1c (HbA1c) (-0.447, 95% CI: 0.085 to 0.810, I²=0%, P=0.0155) in the kidney transplant population. The mortality benefits of SGLT-2 inhibitors in the kidney transplant population have been shown in observational studies with large sample sizes. Despite the benefits of SGLT-2 inhibitors on metabolic outcomes and their satisfactory safety profiles represented in most eligible studies, these medications should be used with caution in patients with SOT, particularly in high-risk patients. Additional well-designed studies are needed to reveal the efficacy and safety of SGLT-2 inhibitors in patients with SOT.
Correction to: Empagliflozin and colchicine in patients with reduced left ventricular ejection fraction following ST-elevation myocardial infarction: a randomized, double-blinded, three-arm parallel-group, controlled trial (European Journal of Clinical Pharmacology, (2024), 80, 1, (93-104), 10.1007/s00228-023-03582-5)
Sajad Khiali, Mohammadreza Taban-Sadeghi, Parvin Sarbakhsh, Naser Khezerlouy-Aghdam, Taher Entezari-Maleki
European Journal of Clinical Pharmacology, 2024
Empagliflozin and colchicine in patients with reduced left ventricular ejection fraction following ST-elevation myocardial infarction: a randomized, double-blinded, three-arm parallel-group, controlled trial
Sajad Khiali, Mohammadreza Taban-Sadeghi, Parvin Sarbakhsh, Naser Khezerlouy-Aghdam, Taher Entezari-Maleki
European Journal of Clinical Pharmacology, 2024
Effects of Allopurinol in the Prevention of Periprocedural Myocardial Injury Following Elective Percutaneous Coronary Intervention: A Randomized Clinical Trial
Naser Aslanabadi, Elnaz Khani, Sajad Khiali, Haleh Rezaee, Saba Pishdad, et al.
Pharmaceutical Sciences, 2024
Background: Periprocedural myocardial injury (PMI) after percutaneous coronary intervention (PCI) is a substantial health issue with a high mortality rate. Inflammation and oxidative stress are major contributing factors to PMI. Allopurinol inhibits xanthine oxidase (XO)-induced oxidative stress and has potential cardiovascular benefits. Methods: This randomized clinical trial evaluated 110 patients admitted to elective PCI. Patients were assigned to receive either a 1200 mg loading dose of allopurinol 2 hours before the procedure (n = 55) or the standard pretreatment (n = 55). The creatine kinase-MB (CK-MB) and cardiac troponin I (cTnI) levels were measured in both groups at the baseline, 8, and 24 hours after PCI. Results: There were no significant differences in the CK-MB levels at baseline (P = 0.71), 8 (P = 0.26), and 24 hours (P = 0.88) after PCI between the two groups. No significant changes in the cTnI levels at baseline (P = 0.26), 8 (P = 0.80), and 24 hours (P = 0.89) after the PCI were also noted. The mean difference for CK-MB and cTnI changes was not different between the two groups. Conclusion: Our study revealed that allopurinol did not reduce cardiac-specific enzymes. Further studies are required to evaluate the impact of allopurinol on preventing PCI-related myocardial injury.
Effects of citalopram on blood pressure control in depressive patients with hypertension: A randomized clinical trial
Hossein Namdar, Elnaz Khani, Sajad Khiali, Naser Safaie, Hedieh Ameli, et al.
Journal of Cardiovascular and Thoracic Research, 2024
Introduction: Since there is a bi‐directional interaction between hypertension and depression, we aimed to evaluate the effects of citalopram administration in the management of hypertension. Methods: A randomized clinical trial was conducted on 72 patients with concomitant depression and hypertension. The intervention group (n=41) received citalopram 20 mg daily plus anti-hypertensive standard treatment, while the control group (n=31) received only the standard treatment. The study’s primary endpoint was in-office blood pressure (BP) measurement at baseline and home BP monitoring in the first and second months after entering the study. Results: There were no significant differences in baseline systolic BP (163.3±19.6 vs.164.2±20.3 mm Hg; P=0.910) and diastolic BP (94.5±13.8 vs. 88.2±14.4; P=0.071). After one month, diastolic BP (82.7±11.7 vs. 77.09±12.2; P=0.023) was significantly higher in the control group compared to the intervention group. Two months after the intervention, systolic BP (133.8±16.5 vs. 124.5±12.4; P=0.009) and diastolic BP (80.7±10.3 vs. 73.7±9.7; P=0.002) were significantly decreased in the intervention group compared to the control group. Conclusion: This study supported the beneficial effects of citalopram in lowering BP in patients with concomitant depression and hypertension.
SGLT2 Inhibitors’ Cardiovascular Benefits in Individuals Without Diabetes, Heart Failure, and/or Chronic Kidney Disease: A Systematic Review
Sajad Khiali, Mohammadreza Taban‐Sadeghi, Parvin Sarbakhsh, Naser Khezerlouy‐Aghdam, Afra Rezagholizadeh, et al.
Journal of Clinical Pharmacology, 2023
Despite the growing body of evidence regarding the beneficial cardiovascular effects of sodium–glucose cotransporter‐2 (SGLT2) inhibitors, clinical data in individuals without diabetes, heart failure (HF), and/or chronic kidney disease (CKD) is limited. A systematic review of the literature was conducted in PubMed, Scopus, Web of Science, Cochrane Library, and Google Scholar, from database inception until May 4, 2023, to explore new evidence of SGLT2 inhibitors’ cardiovascular benefits in individuals without diabetes, HF, and/or CKD. A total of 1156 individuals from 14 studies (13 randomized controlled trials and 1 nonrandomized study) were included. The results showed the benefits of SGLT2 inhibitors on blood pressure, weight, and body mass index in this population with an acceptable safety profile. The current evidence supports the potential role of SGLT2 inhibitors as primary prevention in individuals without diabetes, HF, and/or CKD. This review may shed light on the use of SGLT2 inhibitors in conditions such as stage A HF and metabolic syndrome. The literature trend is going toward uncovering SGLT2 inhibitors’ role in stage B HF, different types of myocardial infarction, and cardiac arrhythmias.
Empagliflozin and colchicine in patients with reduced left ventricular ejection fraction following ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: a study protocol for a randomized, double-blinded, three-arm parallel-group, controlled trial
Sajad Khiali, Mohammadreza Taban-Sadeghi, Parvin Sarbakhsh, Naser Khezerlouy-Aghdam, Hossein Namdar, et al.
Trials, 2023
Background Patients with acute myocardial infarction are at greater risk for chronic heart failure and mortality. Currently, there is limited evidence supporting the beneficial effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular outcomes in non-diabetic patients with reduced left ventricular ejection fraction following acute myocardial infarction. Furthermore, the clinical effects of the combination of standard-dose sodium-glucose cotransporter-2 inhibitors with colchicine and high-dose sodium-glucose cotransporter-2 inhibitors in this setting have not been evaluated yet. Methods A prospective, double-blinded, parallel-group, placebo control randomized trial will be carried out at Shahid Madani Heart Center, the largest teaching referral hospital for cardiovascular diseases, affiliated with Tabriz University of Medical Sciences. A total of 105 patients with reduced left ventricular ejection fraction (≤ 40%) following the first episode of ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention with stent insertion will be randomized 1:1:1 to receive empagliflozin 10 mg daily, a combination of empagliflozin 10 mg daily and colchicine 0.5 mg twice daily, or empagliflozin 25 mg daily for 12 weeks. The primary outcomes are changes in the New York Heart Association functional classification and high-sensitivity C-reactive protein from the randomization through week 4 and week 12. Discussion The present study will be the first trial to evaluate the efficacy and safety of early treatment with the combination of standard-dose empagliflozin and colchicine as well as high-dose empagliflozin in non-diabetic patients with reduced left ventricular ejection fraction following ST-elevation myocardial infarction. The results of this research will represent a significant step forward in the treatment of patients with acute myocardial infarction. Trial registration Clinical trial ID: IRCT20111206008307N39. Registration date: 27 October 2022. Graphical Abstract
Effect of Caffeine Consumption on Cardiovascular Disease: An Updated Review
Sajad Khiali, Amin Agabalazadeh, Hadi Sahrai, Hossein Bannazadeh Baghi, Gholamreza Rahbari Banaeian, et al.
Pharmaceutical Medicine, 2023
Tocilizumab in COVID-19 management: Addressing time of starting treatment
Sajad Khiali, Taher Entezari-Maleki
European Journal of Hospital Pharmacy, 2023
Current evidence of COVID-19 vaccination-related cardiovascular events
Sajad Khiali, Afra Rezagholizadeh, Hossein Behzad, Hossein Bannazadeh Baghi, Taher Entezari-Maleki
Postgraduate Medicine, 2023
Colchicine for the Prevention of Myocardial Injury Following Elective PCI: A Randomized Clinical Trial
Naser Aslanabadi, Sajad Khiali, Saeid Joudi, Milad Mamdouhi, Taher Entezari-Maleki
Pharmaceutical Sciences, 2022
New Variants of SARS-CoV-2 and Next Generation of COVID-19 Treatments
Sajad Khiali, Taher Entezari‐Maleki
Journal of Clinical Pharmacology, 2022
SARS-CoV-2 and probable lung cancer risk
Sajad Khiali, Afra Rezagholizadeh, Taher Entezari-Maleki
Bioimpacts, 2022
Comprehensive review on molnupiravir in COVID-19: A novel promising antiviral to combat the pandemic
Sajad Khiali, Elnaz Khani, Samineh B Rouy, Taher Entezari-Maleki
Future Microbiology, 2022
Investigational antiviral drugs for the treatment of COVID-19 patients
Samineh Beheshtirouy, Elnaz Khani, Sajad Khiali, Taher Entezari-Maleki
Archives of Virology, 2022
Potential pharmacologic treatments for COVID-19 smell and taste loss: A comprehensive review
Elnaz Khani, Sajad Khiali, Samineh Beheshtirouy, Taher Entezari-Maleki
European Journal of Pharmacology, 2021
The Effects of Allopurinol on Levels of Cardiac Troponin Following Non-ST Elevation Myocardial Infarction: A Pilot Randomized Clinical Trial
Sajad Khiali, Parvin Sarbakhsh, Sina Mashayekhi, Elham Mohamadrezapour, Samaneh Dousti, et al.
Pharmaceutical Sciences, 2021
Potential roles of vitamins in the management of COVID-19: A comprehensive review
Homa Rezaei, Sajad Khiali, Haleh Rezaee, Hossein Bannazadeh Baghi, Matin Pourghasem, et al.
Pharmaceutical Sciences, 2021
Therapeutic Application of Corticosteroids in COVID-19: A Focus on Optimum Dose and Duration of Therapy
Sajad Khiali, Taher Entezari‐Maleki
Journal of Clinical Pharmacology, 2021
The Impact of Clinical Pharmacist Interventions on Medication Errors Management in the Postoperative Cardiac Intensive Care Unit
Pharmaceutical Sciences, 2021
Pharmacist-Directed Self-Management of Blood Pressure Versus Conventional Management in Patients with Hypertension: A Randomized Control Trial
Sajad Khiali, Naser Khezerlo-aghdam, Hossein Namdar, Taher Entezari-Maleki
High Blood Pressure and Cardiovascular Prevention, 2021
Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis
Afra Rezagholizadeh, Sajad Khiali, Parvin Sarbakhsh, Taher Entezari-Maleki
European Journal of Pharmacology, 2021
Potential COVID-19 Therapeutic Agents and Vaccines: An Evidence-Based Review
Elnaz Khani, Sajad Khiali, Taher Entezari‐Maleki
Journal of Clinical Pharmacology, 2021

RECENT SCHOLAR PUBLICATIONS

Pentoxifylline Effects on Late-Onset Sepsis in Preterm Neonates: A Pilot Randomized Clinical Trial
MB Hosseini, MM Gharehbaghi, P Sarbakhsh, DB Mohammadi, H Asham, ...
Pharmaceutical Sciences 32 (1), 160-166 , 2026
2026
Efficacy and Safety of SGLT2 Inhibitors in Individuals with Sold Organ Transplantation: A Systematic Review and Meta-analysis
S Khiali, M Ardalan, A Sharifi, A Sadrazar, A Rezagholizadeh, ...
Pharmaceutical Sciences 31 (4), 357-378 , 2025
2025
Effects of colchicine on depression scale scores of patients with chronic heart failure with reduced ejection fraction: A randomized clinical trial
M Taban-Sadeghi, S Khiali, M Karimi, M Shahidi, E Khani, Z Mousavi, ...
Journal of Cardiovascular and Thoracic Research 17 (3), 206 , 2025
2025
Citations: 1
Omega-3 fatty acid supplementation in solid organ transplant recipients: A systematic review and meta-analysis of randomized controlled trials
S Samankan, A Gharekhani, S Khiali, A Rezagholizadeh, ...
Clinical nutrition ESPEN , 2025
2025
Citations: 2
Effects of citalopram on blood pressure control in depressive patients with hypertension: A randomized clinical trial
H Namdar, E Khani, S Khiali, N Safaie, H Ameli, GR Banaeian, ...
Journal of Cardiovascular and Thoracic Research 16 (1), 49 , 2024
2024
Citations: 2
Correction to: Empagliflozin and colchicine in patients with reduced left ventricular ejection fraction following ST-elevation myocardial infarction: a randomized, double …
S Khiali, M Taban-Sadeghi, P Sarbakhsh, N Khezerlouy-Aghdam, ...
European Journal of Clinical Pharmacology 80 (2), 301-303 , 2024
2024
Empagliflozin and colchicine in patients with reduced left ventricular ejection fraction following ST-elevation myocardial infarction: a randomized, double-blinded, three-arm …
S Khiali, M Taban-Sadeghi, P Sarbakhsh, N Khezerlouy-Aghdam, ...
European Journal of Clinical Pharmacology 80 (1), 93-104 , 2024
2024
Citations: 10
SGLT2 inhibitors’ cardiovascular benefits in individuals without diabetes, heart failure, and/or chronic kidney disease: a systematic review
S Khiali, M Taban‐Sadeghi, P Sarbakhsh, N Khezerlouy‐Aghdam, ...
The Journal of Clinical Pharmacology 63 (12), 1307-1323 , 2023
2023
Citations: 20
Empagliflozin and colchicine in patients with reduced left ventricular ejection fraction following ST-elevation myocardial infarction: a randomized, double-blinded, three-arm …
TEM Sajad Khiali, Mohammadreza Taban-Sadeghi, Parvin Sarbakhsh, Naser ...
European Journal of Clinical Pharmacology , 2023
2023
Empagliflozin and colchicine in patients with reduced left ventricular ejection fraction following ST-elevation myocardial infarction undergoing primary percutaneous coronary …
S Khiali, M Taban-Sadeghi, P Sarbakhsh, N Khezerlouy-Aghdam, ...
Trials 24 (1), 645 , 2023
2023
Citations: 4
No. 2023-25: Therapeutic Drug Monitoring of Mycophenolate in Combination with Cyclosporine or Tacrolimus in Kidney Transplant Patients.
S Khiali, H Tayebi, A Gharekhani
International Journal of Organ Transplantation Medicine 14 (4) , 2023
2023
Effect of caffeine consumption on cardiovascular disease: an updated review
S Khiali, A Agabalazadeh, H Sahrai, H Bannazadeh Baghi, ...
Pharmaceutical Medicine 37 (2), 139-151 , 2023
2023
Citations: 17
Tocilizumab in COVID-19 management: addressing time of starting treatment
S Khiali, T Entezari-Maleki
European Journal of Hospital Pharmacy 30 (2), e9-e9 , 2023
2023
Citations: 2
Current evidence of COVID-19 vaccination-related cardiovascular events
S Khiali, A Rezagholizadeh, H Behzad, H Bannazadeh Baghi, ...
Postgraduate Medicine 135 (2), 102-120 , 2023
2023
Citations: 8
Evaluation Effects of Colchicine and Empagliflozin in Heart Failure with Reduced Ejection Fraction: A Randomized Clinical Trial
S Khiali
Tabriz University of Medical Sciences, School of Pharmacy , 2023
2023
Study Protocol
S Khiali, M Taban‑Sadeghi, P Sarbakhsh, N Khezerlouy‑Aghdam, ...
2023
Effects of Allopurinol in the Prevention of Periprocedural Myocardial Injury Following Elective Percutaneous Coronary Intervention: A Randomized Clinical Trial
N Aslanabadi, E Khani, S Khiali, H Rezaee, S Pishdad, T Entezari-Maleki
Pharmaceutical Sciences 5, 6 , 2023
2023
New Variants of SARS‐CoV‐2 and Next Generation of COVID‐19 Treatments.
S Khiali, T Entezari‐Maleki
Journal of Clinical Pharmacology 62 (9) , 2022
2022
Citations: 2
Comprehensive review on molnupiravir in COVID-19: a novel promising antiviral to combat the pandemic
S Khiali, E Khani, S B Rouy, T Entezari-Maleki
Future Microbiology 17 (5), 377-391 , 2022
2022
Citations: 26
Investigational antiviral drugs for the treatment of COVID-19 patients
S Beheshtirouy, E Khani, S Khiali, T Entezari-Maleki
Archives of virology 167 (3), 751-805 , 2022
2022
Citations: 13

MOST CITED SCHOLAR PUBLICATIONS

Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis
A Rezagholizadeh, S Khiali, P Sarbakhsh, T Entezari-Maleki
European journal of pharmacology 897, 173926 , 2021
2021
Citations: 132
A comprehensive review of tocilizumab in COVID‐19 acute respiratory distress syndrome
S Khiali, E Khani, T Entezari‐Maleki
The Journal of Clinical Pharmacology 60 (9), 1131-1146 , 2020
2020
Citations: 104
Potential pharmacologic treatments for COVID-19 smell and taste loss: A comprehensive review
E Khani, S Khiali, S Beheshtirouy, T Entezari-Maleki
European journal of pharmacology 912, 174582 , 2021
2021
Citations: 87
A comprehensive review on sarilumab in COVID-19
S Khiali, A Rezagholizadeh, T Entezari-Maleki
Expert Opinion on Biological Therapy 21 (5), 615-626 , 2021
2021
Citations: 48
Potential COVID‐19 therapeutic agents and vaccines: an evidence‐based review
E Khani, S Khiali, T Entezari‐Maleki
The Journal of Clinical Pharmacology 61 (4), 429-460 , 2021
2021
Citations: 33
Isotretinoin; A review on the utilization pattern in pregnancy
S Khiali, A Gharekhani, T Entezari-Maleki
Advanced Pharmaceutical Bulletin 8 (3), 377 , 2018
2018
Citations: 31
Comprehensive review on molnupiravir in COVID-19: a novel promising antiviral to combat the pandemic
S Khiali, E Khani, S B Rouy, T Entezari-Maleki
Future Microbiology 17 (5), 377-391 , 2022
2022
Citations: 26
SGLT2 inhibitors’ cardiovascular benefits in individuals without diabetes, heart failure, and/or chronic kidney disease: a systematic review
S Khiali, M Taban‐Sadeghi, P Sarbakhsh, N Khezerlouy‐Aghdam, ...
The Journal of Clinical Pharmacology 63 (12), 1307-1323 , 2023
2023
Citations: 20
Anticoagulation in COVID-19: DDI perspective
S Khiali, T Entezari-Maleki
Clinical and Applied Thrombosis/Hemostasis 26, 1076029620959457 , 2020
2020
Citations: 18
Effect of caffeine consumption on cardiovascular disease: an updated review
S Khiali, A Agabalazadeh, H Sahrai, H Bannazadeh Baghi, ...
Pharmaceutical Medicine 37 (2), 139-151 , 2023
2023
Citations: 17
Therapeutic application of corticosteroids in COVID‐19: a focus on optimum dose and duration of therapy
S Khiali, T Entezari‐Maleki
Journal of Clinical Pharmacology 61 (9), 1145 , 2021
2021
Citations: 17
SARS-CoV-2 and probable lung cancer risk
TEM Sajad Khiali, Afra Rezagholizadeh
BioImpacts , 2022
2022
Citations: 15
Investigational antiviral drugs for the treatment of COVID-19 patients
S Beheshtirouy, E Khani, S Khiali, T Entezari-Maleki
Archives of virology 167 (3), 751-805 , 2022
2022
Citations: 13
Empagliflozin and colchicine in patients with reduced left ventricular ejection fraction following ST-elevation myocardial infarction: a randomized, double-blinded, three-arm …
S Khiali, M Taban-Sadeghi, P Sarbakhsh, N Khezerlouy-Aghdam, ...
European Journal of Clinical Pharmacology 80 (1), 93-104 , 2024
2024
Citations: 10
Current evidence of COVID-19 vaccination-related cardiovascular events
S Khiali, A Rezagholizadeh, H Behzad, H Bannazadeh Baghi, ...
Postgraduate Medicine 135 (2), 102-120 , 2023
2023
Citations: 8
Potential roles of vitamins in the management of COVID-19: A comprehensive review
H Rezaei, S Khiali, H Rezaei, H Rezaee, BH Bannazadeh, ...
PHARMACEUTICAL SCIENCES 27, 29-49 , 2021
2021
Citations: 6
The impact of clinical pharmacist interventions on medication errors management in the postoperative cardiac intensive care unit
N Safaie, H Azizi, S Khiali, T Entezari-Maleki
Pharmaceutical Sciences 27 (3), 433-438 , 2020
2020
Citations: 6
Pharmacist-Directed Self-Management of Blood Pressure Versus Conventional Management in Patients with Hypertension: A Randomized Control Trial: S. Khiali et al.
S Khiali, N Khezerlo-Aghdam, H Namdar, T Entezari-Maleki
High Blood Pressure & Cardiovascular Prevention 28 (3), 283-290 , 2021
2021
Citations: 5
Empagliflozin and colchicine in patients with reduced left ventricular ejection fraction following ST-elevation myocardial infarction undergoing primary percutaneous coronary …
S Khiali, M Taban-Sadeghi, P Sarbakhsh, N Khezerlouy-Aghdam, ...
Trials 24 (1), 645 , 2023
2023
Citations: 4
Vancomycin utilization evaluation in a major teaching hospital in West of Iran
S Khiali, S Eskandari, H Hamishehkar, P Maroufi, H Rezaee
Journal of Pharmaceutical Care , 2020
2020
Citations: 4

Sajad Khiali

RESEARCH INTERESTS

Scopus Publications

RECENT SCHOLAR PUBLICATIONS

MOST CITED SCHOLAR PUBLICATIONS